Anti-PACAP Therapy: Slate Medicines Raises $130M to Advance Migraine Prevention
Anti-PACAP Therapy Company Slate Medicines Launches with $130M Anti-PACAP therapy developer Slate Medicines has launched with $130 million in Series A financing to advance a next-generation migraine prevention treatment....

